<DOC>
	<DOC>NCT01655082</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety profile of a repeated application of a new transdermal patch compared to a reference product during 3 weeks, in a large population.</brief_summary>
	<brief_title>Nicotine Patch Safety Study</brief_title>
	<detailed_description />
	<mesh_term>Nicotine</mesh_term>
	<criteria>Male or female aged more than 18 years Regular smoker motivated to stop tobacco consumption Current smoker of &gt; or = 20 cigarettes/day and &lt; or = 25 cigarettes/day or Fagerstr√∂m score &gt; or = 5 (for smokers between 10 to 20 cigarettes/day) Any visible skin disorder, abnormal skin pigmentation or other dermatologic disease which, in the opinion of the investigator would interfere with the assessment of the different parameters Current or past serious chronic cardiovascular, renal, hepatic, gastrointestinal (including duodenal or gastric ulcer), endocrine, hematological, neuropsychiatric, immunosuppressive condition or allergic disease, myopathies, epileptic seizures, bleeding tendency, cancer History of angina pectoris, myocardial infarction or stroke in the previous 3 months, coronary artery vasospasm, cardiac arrhythmia, acute stroke Clinically relevant abnormal findings on the physical examination (e.g large scars on the application zone)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Smoking cessation</keyword>
	<keyword>Nicotine</keyword>
	<keyword>Tobacco Use Disorder</keyword>
	<keyword>Central Nervous System Agents</keyword>
</DOC>